Overview

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Terminated

Trial end date:
2017-04-05

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences
Sierra Oncology, Inc.

Treatments:

Capecitabine
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Oxaliplatin